MedPage Today (7/16, Smith) reports that researchers found that “a drug being studied as a treatment for extensively drug-resistant tuberculosis (XDR-TB) had durable efficacy in a small trial.” One “year after the end of treatment with linezolid (Zyvox), combined with a background regimen, 27 of 38 patients had negative results on sputum culture, according to Clifton Barry III, PhD, of the National Institute of Allergy and Infectious Disease in Bethesda, Md., and colleagues.” Meanwhile, “in another brief report, investigators said post-hoc analysis of three trials of the investigational drug delamanid – a mycobacterial cell wall synthesis inhibitor – suggests it, too, is effective against XDR-TB.” The findings were published in the New England Journal of Medicine.
Here are the link to the published article.
No comments:
Post a Comment
Please leave your comments